Singh Amar M, Adjan Steffey Valeriya V, Yeshi Tseten, Allison Daniel W
Transposagen Biopharmaceuticals, Kentucky, USA.
Hera BioLabs, Kentucky, USA.
J Stem Cell Regen Biol. 2015;1(1). Epub 2015 Nov 5.
The recent emergence of targeted nucleases has opened up new opportunities for performing genetic modifications with human pluripotent stem cells (hPSCs). These modifications can range from the creation of a routine knock-out to the more challenging single point-mutation. For both the new and established user, deciding on the best approach for the specific modification of interest can be an arduous task, as new and improved technologies are rapidly and continuously being developed. The choices between the reagents and methodologies depends entirely on the end-goal of the experiments and the locus to be modified. Investigators need to decide on the best nuclease to use for each experiment from among Zinc-Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 that would result in the highest likelihood of success with the fewest pitfalls. Furthermore, there have been significant improvements over the first-generation nucleases, such as the development of the dimeric CRISPR RNA-guided Fok1 nucleases (RFNs, marketed as NextGEN™ CRISPR) that reduces the "off-target" mutation rate, providing further options for investigators. Should researchers need to perform a point mutation, then considerations must be made between using single-stranded oligo-deoxynucleotides (ssODN) as the donor for homology-directed repair or utilizing a selection cassette within a donor vector in combination with an excision-only piggyBac™ transposase to leave a seamless edit. In this review, we will provide a general overview of the current technologies, along with methodologies for generating point mutations, while considering both their pros and cons.
靶向核酸酶的最新出现为利用人类多能干细胞(hPSC)进行基因改造开辟了新机遇。这些改造范围可从常规的基因敲除到更具挑战性的单点突变。对于新手和有经验的用户而言,为特定感兴趣的改造确定最佳方法可能是一项艰巨任务,因为新的和改进的技术正在迅速且持续地发展。试剂和方法之间的选择完全取决于实验的最终目标以及要改造的位点。研究人员需要从锌指核酸酶(ZFN)、转录激活样效应核酸酶(TALEN)和规律成簇间隔短回文重复序列(CRISPR)/Cas9中为每个实验确定最佳核酸酶,这将以最少的陷阱获得最高的成功可能性。此外,与第一代核酸酶相比有了显著改进,例如二聚体CRISPR RNA引导的Fok1核酸酶(RFN,商品名为NextGEN™ CRISPR)的开发降低了“脱靶”突变率,为研究人员提供了更多选择。如果研究人员需要进行点突变,那么必须考虑是使用单链寡脱氧核苷酸(ssODN)作为同源定向修复的供体,还是在供体载体中使用选择盒并结合仅用于切除的piggyBac™转座酶以实现无缝编辑。在本综述中,我们将概述当前技术以及产生点突变的方法,同时考虑它们各自的优缺点。